Table of Contents
Overview
New York, NY – May 28, 2025 – The Global Preimplantation Genetic Diagnosis Market size is expected to be worth around US$ 2.4 billion by 2034 from US$ 0.9 billion in 2024, growing at a CAGR of 10.4% during the forecast period 2025 to 2034.
Preimplantation Genetic Diagnosis (PGD) is a transformative assisted reproductive technology that enables the genetic screening of embryos prior to implantation. It is primarily used in conjunction with in vitro fertilization (IVF) to detect genetic abnormalities, allowing the transfer of embryos that are free from specific inherited disorders. PGD provides couples with a powerful tool to prevent the transmission of serious genetic diseases, including cystic fibrosis, Tay-Sachs disease, and sickle cell anemia.
This diagnostic approach involves extracting one or more cells from an embryo at the blastocyst stage, followed by genetic testing to identify chromosomal abnormalities or gene mutations. Only embryos that pass the screening criteria are selected for implantation, thereby enhancing the chances of a healthy pregnancy.
PGD is especially beneficial for individuals with known genetic disorders, carriers of single-gene mutations, women of advanced maternal age, and those with a history of recurrent miscarriages. It also supports family balancing and HLA matching in cases requiring sibling stem cell transplants.
As awareness of genetic health continues to grow, PGD is gaining prominence across fertility clinics worldwide. With advancements in genome sequencing technologies and regulatory support in select countries, the accessibility and reliability of PGD are improving steadily. Preimplantation Genetic Diagnosis represents a significant step forward in personalized reproductive care, offering families the opportunity to make informed decisions and reduce the risk of inherited conditions.
Key Takeaways
- In 2023, the global Preimplantation Genetic Diagnosis (PGD) market generated USD 9 billion in revenue and is projected to reach USD 24 billion by 2033, growing at a CAGR of 10.4% during the forecast period.
- Based on test type, the market is segmented into preimplantation genetic screening, preimplantation genetic diagnosis, and comprehensive chromosomal screening. Among these, preimplantation genetic diagnosis held the leading position, accounting for 55.8% of the market share in 2023.
- In terms of technology, the market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), and microarray. Next-generation sequencing dominated the segment, capturing 59.1% of the total market share.
- Regarding application, the PGD market is segmented into genetic disorder prevention, infertility treatment, and sex selection. The infertility treatment segment led the market, contributing 54.3% of the total revenue in 2023.
- In the end-user category, the market comprises research laboratories, fertility clinics, and hospitals. Fertility clinics emerged as the dominant segment, accounting for a 57.6% revenue share.
- Regionally, North America held the largest share, commanding 39.6% of the global PGD market in 2023.
Segmentation Analysis
- Test Type Analysis: In 2023, the preimplantation genetic diagnosis (PGD) segment dominated with a 55.8% market share. This was driven by growing demand for genetic screening prior to embryo implantation. PGD helps detect specific inherited disorders, making it crucial in assisted reproductive technology (ART). Rising awareness of genetic diseases and advancements in genomics are expected to boost PGD adoption. Additionally, increasing preference for family planning that ensures healthy offspring will further support this segment’s continued growth.
- Technology Analysis: Next-generation sequencing (NGS) held the largest market share of 59.1% in 2023 due to its accuracy and speed in analyzing genetic data. NGS enables comprehensive genetic screening and detects a wide range of abnormalities, making it highly effective for PGD. Its cost-efficiency and detailed results compared to traditional methods have accelerated its adoption. With continued advancements in automation and accuracy, NGS is expected to see wider integration in reproductive medicine and PGD applications.
- Application Analysis: The infertility treatment segment led the market with a 54.3% share in 2023, driven by rising demand for genetic screening during fertility treatments. PGD plays a key role in helping couples prevent inherited disorders, especially in cases involving advanced maternal age or family history of genetic diseases. The growing use of IVF and interest in sex selection for family balancing are also boosting demand. As personalized reproductive medicine gains traction, PGD adoption in infertility care is likely to grow.
- End-user Analysis: Fertility clinics accounted for the highest revenue share at 57.6% in 2023, reflecting their central role in delivering IVF and embryo screening services. The rising incidence of infertility globally and increasing patient interest in advanced, personalized reproductive options are fueling this trend. Clinics are integrating PGD as a standard offering to enhance embryo selection and treatment success. As outcomes improve and demand for healthy childbirth rises, the fertility clinic segment is expected to continue expanding.
Market Segments
By Test Type
- Preimplantation Genetic Screening
- Preimplantation Genetic Diagnosis
- Comprehensive Chromosomal Screening
By Technology
- Next Generation Sequencing
- Polymerase Chain Reaction
- Microarray
By Application
- Genetic Disorder Prevention
- Infertility Treatment
- Sex Selection
By End-user
- Research Laboratories
- Fertility Clinics
- Hospitals
Regional Analysis
In 2023, North America led the global Preimplantation Genetic Diagnosis (PGD) market, capturing the largest revenue share of 39.6%. This dominance can be attributed to rising awareness of genetic disorders, advancements in reproductive technologies, and the growing demand for personalized medicine. The region has seen an increase in IVF procedures and fertility clinics offering PGD, further boosting market growth. PGD enables early detection of inherited genetic disorders, making it a preferred choice for prospective parents seeking healthy pregnancies. The adoption of PGD for sex selection and comprehensive screening of genetic abnormalities is also rising, contributing to regional expansion.
The Asia Pacific region is projected to register the fastest CAGR during the forecast period. This growth is fueled by increasing healthcare investments, expanding access to IVF, and growing awareness of genetic testing across countries like China, India, and Japan. In December 2023, Progenesis launched a Genetic Laboratory in New Delhi and an AI & Bioinformatics Data Centre in Chennai, reflecting regional advancements. Supportive government initiatives and an increasing number of fertility clinics are expected to sustain this momentum, positioning Asia Pacific as a key emerging market for PGD.
Emerging Trends
- Shift toward non-invasive embryo testing: In recent years, non-invasive sampling methods such as analyzing cell-free DNA in spent culture media or blastocoel fluid have been introduced to reduce risks associated with embryo biopsy. These approaches allow genetic material to be obtained without directly removing cells from embryos, thereby minimizing potential damage during testing and addressing ethical and legal concerns. Non-invasive methods are expected to become more common in clinical IVF settings over the next five years as validation studies advance.
- Widespread adoption of next-generation sequencing: Next-generation sequencing (NGS) has increasingly replaced older techniques like FISH for preimplantation genetic testing for aneuploidy (PGT-A). NGS offers higher resolution, detecting single-nucleotide variants and mosaicism, and supports comprehensive chromosome screening in a single assay. Its high throughput capability has streamlined laboratory workflows and reduced per-cycle costs, making NGS-based PGT-A the standard in many IVF clinics.
- Integration of artificial intelligence for embryo selection: Machine-learning algorithms and time-lapse imaging systems are now being used to assess embryo development dynamics and predict implantation potential. Fully automated AI models, trained on large datasets of embryo morphokinetics, can rank embryos objectively and consistently, improving selection accuracy. Early studies demonstrate that AI-assisted scoring matches or exceeds human grading, suggesting wider clinical uptake is imminent.
- Expansion of clinical indications beyond monogenic diseases: The scope of PGD/PGT has broadened to include screening for late-onset disorders (e.g., BRCA mutations), HLA matching for sibling stem-cell donation, and polygenic risk assessment. Such applications address an increasing demand among couples with advanced maternal age or recurrent pregnancy loss, as well as those seeking to reduce familial cancer risk. Reports indicate that over one third of U.S. ART centers now offer these expanded services alongside traditional monogenic testing.
Use Cases
- Rapid growth of PGT in IVF cycles: Between 2014 and 2018 in the United States, the absolute number of IVF retrieval cycles using PGT rose markedly from 18 059 to 58 827. This growth translated to an increase in the share of all retrieval cycles using PGT from 17.2 % in 2014 to 44.9 % in 2018, reflecting a significant shift toward genetic screening in routine IVF practice.
- Variation in PGT use by maternal age: Utilization of PGT varies by age group. In 2018, PGT was applied in 27.0 % of cycles for women under 35 years, rising to 41.3 % for those aged 38–40, and then declining to 29.0 % for women aged 43 years and older. This pattern underscores targeted use of genetic testing where aneuploidy risk is highest.
Conclusion
In conclusion, Preimplantation Genetic Diagnosis (PGD) is reshaping reproductive healthcare by enabling early detection of genetic abnormalities, improving IVF success rates, and supporting personalized fertility treatments. The market is expanding steadily, driven by technological advancements like next-generation sequencing and growing awareness of genetic disorders.
Fertility clinics are at the forefront of this growth, with North America leading the market and Asia Pacific emerging rapidly. Trends such as non-invasive embryo testing and AI-based embryo selection signal a shift toward safer, more precise reproductive options. As demand rises, PGD is poised to become a standard component of assisted reproductive care worldwide.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
